The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse

Megan Laudenbach, Federico Baruffaldi, Jeffrey S. Vervacke, Mark D. Distefano, Philip J. Titcombe, Daniel L. Mueller, Noah J. Tubo, Thomas S. Griffith, Marco Pravetoni

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels. We hypothesize that individual variability in the number of naive and early-activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy. Using a model vaccine against the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for an oxycodone-based hapten (6OXY) was analyzed by flow cytometry paired with Ag-based magnetic enrichment. A higher frequency of 6OXY-specific B cells in either spleen biopsies or blood, before and after immunization, correlated to subsequent greater oxycodone-specific serum Ab titers and their efficacy in blocking oxycodone distribution to the brain and oxycodone-induced behavior in mice. The magnitude of 6OXY-specific B cell activation and vaccine efficacy was tightly correlated to the size of the CD4+ T cell population. The frequency of enriched 6OXY-specific B cells was consistent across various mouse tissues. These data provide novel evidence that variations in the frequency of naive or early-activated vaccine-specific B and T cells can account for individual responses to vaccines and may predict the clinical efficacy of a therapeutic vaccine.

Original languageEnglish (US)
Pages (from-to)5926-5936
Number of pages11
JournalJournal of Immunology
Volume194
Issue number12
DOIs
StatePublished - Jun 15 2015

Fingerprint

B-Lymphocyte Subsets
Haptens
Oxycodone
Opioid Analgesics
Prescriptions
B-Lymphocytes
Vaccines
Therapeutics
T-Lymphocytes
Cancer Vaccines
Serum
Population
Immunization
Flow Cytometry
Chronic Disease
Spleen
Biopsy
Brain

Cite this

The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. / Laudenbach, Megan; Baruffaldi, Federico; Vervacke, Jeffrey S.; Distefano, Mark D.; Titcombe, Philip J.; Mueller, Daniel L.; Tubo, Noah J.; Griffith, Thomas S.; Pravetoni, Marco.

In: Journal of Immunology, Vol. 194, No. 12, 15.06.2015, p. 5926-5936.

Research output: Contribution to journalArticle

Laudenbach, Megan ; Baruffaldi, Federico ; Vervacke, Jeffrey S. ; Distefano, Mark D. ; Titcombe, Philip J. ; Mueller, Daniel L. ; Tubo, Noah J. ; Griffith, Thomas S. ; Pravetoni, Marco. / The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. In: Journal of Immunology. 2015 ; Vol. 194, No. 12. pp. 5926-5936.
@article{7bf3e6fba56e4868b977532fe070f071,
title = "The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse",
abstract = "Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels. We hypothesize that individual variability in the number of naive and early-activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy. Using a model vaccine against the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for an oxycodone-based hapten (6OXY) was analyzed by flow cytometry paired with Ag-based magnetic enrichment. A higher frequency of 6OXY-specific B cells in either spleen biopsies or blood, before and after immunization, correlated to subsequent greater oxycodone-specific serum Ab titers and their efficacy in blocking oxycodone distribution to the brain and oxycodone-induced behavior in mice. The magnitude of 6OXY-specific B cell activation and vaccine efficacy was tightly correlated to the size of the CD4+ T cell population. The frequency of enriched 6OXY-specific B cells was consistent across various mouse tissues. These data provide novel evidence that variations in the frequency of naive or early-activated vaccine-specific B and T cells can account for individual responses to vaccines and may predict the clinical efficacy of a therapeutic vaccine.",
author = "Megan Laudenbach and Federico Baruffaldi and Vervacke, {Jeffrey S.} and Distefano, {Mark D.} and Titcombe, {Philip J.} and Mueller, {Daniel L.} and Tubo, {Noah J.} and Griffith, {Thomas S.} and Marco Pravetoni",
year = "2015",
month = "6",
day = "15",
doi = "10.4049/jimmunol.1500385",
language = "English (US)",
volume = "194",
pages = "5926--5936",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse

AU - Laudenbach, Megan

AU - Baruffaldi, Federico

AU - Vervacke, Jeffrey S.

AU - Distefano, Mark D.

AU - Titcombe, Philip J.

AU - Mueller, Daniel L.

AU - Tubo, Noah J.

AU - Griffith, Thomas S.

AU - Pravetoni, Marco

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels. We hypothesize that individual variability in the number of naive and early-activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy. Using a model vaccine against the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for an oxycodone-based hapten (6OXY) was analyzed by flow cytometry paired with Ag-based magnetic enrichment. A higher frequency of 6OXY-specific B cells in either spleen biopsies or blood, before and after immunization, correlated to subsequent greater oxycodone-specific serum Ab titers and their efficacy in blocking oxycodone distribution to the brain and oxycodone-induced behavior in mice. The magnitude of 6OXY-specific B cell activation and vaccine efficacy was tightly correlated to the size of the CD4+ T cell population. The frequency of enriched 6OXY-specific B cells was consistent across various mouse tissues. These data provide novel evidence that variations in the frequency of naive or early-activated vaccine-specific B and T cells can account for individual responses to vaccines and may predict the clinical efficacy of a therapeutic vaccine.

AB - Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels. We hypothesize that individual variability in the number of naive and early-activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy. Using a model vaccine against the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for an oxycodone-based hapten (6OXY) was analyzed by flow cytometry paired with Ag-based magnetic enrichment. A higher frequency of 6OXY-specific B cells in either spleen biopsies or blood, before and after immunization, correlated to subsequent greater oxycodone-specific serum Ab titers and their efficacy in blocking oxycodone distribution to the brain and oxycodone-induced behavior in mice. The magnitude of 6OXY-specific B cell activation and vaccine efficacy was tightly correlated to the size of the CD4+ T cell population. The frequency of enriched 6OXY-specific B cells was consistent across various mouse tissues. These data provide novel evidence that variations in the frequency of naive or early-activated vaccine-specific B and T cells can account for individual responses to vaccines and may predict the clinical efficacy of a therapeutic vaccine.

UR - http://www.scopus.com/inward/record.url?scp=84931388918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931388918&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1500385

DO - 10.4049/jimmunol.1500385

M3 - Article

VL - 194

SP - 5926

EP - 5936

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -